- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452331
Assessing Open Access Audio (OAA)
March 13, 2025 updated by: VA Office of Research and Development
An Assessment of Open Access Audio of the Clinical Encounter on Veterans and Their Care
The medical encounter can be overwhelming in term of the amount of information discussed, its technical nature, and the anxiety it can generate.
Easy access to a secure audio recording from any internet enabled device is an available low cost technology that allows patients to "revisit the visit" either alone or sharing with caretakers and family.
It has been introduced and tested outside the VA with evidence that it increases patient recall and understanding and may even improve physician performance.
Little is known, however, about whether and to what extent these effects lead to better outcomes, such as improved treatment plan adherence and chronic disease self-management.
This study is a randomized controlled trial designed ascertain whether easy access to audio recordings of the medical visit improves patients perception that they understand and can manage their own care, and leads to a variety of improved outcomes, such as better blood pressure and diabetes control, and fewer emergency department visits and hospitalizations.
Study Overview
Status
Completed
Conditions
Detailed Description
The study aims to assess (1) the impact of an open access audio (OAA) program on two behaviors (patient activation, treatment plan adherence), and two chronic condition measures (glycosylated hemoglobin, blood pressure); (2) the impact of open access audio on provider communication and on their attention to patient contextual factors (i.e.
individual Veteran's needs and circumstances relevant to planning effective care); and (3) patient, provider, and leadership perceptions of the extent to which the program is safe, not burdensome, and worthwhile at both the start and at two years into the program.
A secondary analysis will descriptively measure the effect size of OAA on ED visits and hospital admissions.
Study Type
Interventional
Enrollment (Actual)
1553
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Jesse Brown VA Medical Center, Chicago, IL
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-1702
- Louis Stokes VA Medical Center, Cleveland, OH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- All patients with scheduled appointments at the participating sites: primary care and diabetes clinics at Jesse Brown VA Medical Center and the Louis Stokes Cleveland VA Medical Center
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: OAA Intervention
Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
|
Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
Other Names:
|
|
Sham Comparator: OAA Physician Aware Control
Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
|
Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
Other Names:
|
|
Placebo Comparator: OAA Physician Unaware Control
Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
|
Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycosylated Hemoglobin (HgB A1c)
Time Frame: 4-6 months
|
This outcome tests the hypothesis that HgB A1c improves in patients with Hgb A1c > 7 when they have access to an audio recording of their discussion with their provider regarding diabetes management compared to when they do no.
An improvement is defined as a decrease of 1% or more.
|
4-6 months
|
|
Patient Activation Measure (PAM)
Time Frame: 2 weeks
|
This outcome tests the hypothesis that patient activation is higher in patients when they have access to an audio recording of their visit with their provider compared to when they do not.
Patients are called by phone post visit to answer PAM 10, a 10 item questionnaire with a 5 point Likert response that scores their perceived knowledge, skills, and confident in their capacity to follow their treatment plan with scores from 0-100.
A higher score indicates higher patient activation.
|
2 weeks
|
|
Blood Pressure
Time Frame: 6 months
|
This outcome tests the hypothesis that blood pressure control improves in patients with blood pressure > 140/90 when they have access to an audio recording of their visit with their provider regarding blood pressure management compared to those who do not.
An improvement in blood pressure is defined as a reduction of 10 or more mmHg in either the systolic or diastolic blood pressure.
|
6 months
|
|
Return Visit Adherence (RVA)
Time Frame: From index visit to end of study data collection, an average of 512 days
|
This outcome tests the hypothesis that return visit adherence (RVA) improves in patients with non-adherence when they have access to an audio recording of their discussion with their provider.
The outcome is the predicted proportion of visits scheduled between the time of the index visit and the end of the study that the patient attends (adjusted for clinic).
For example, a value of 0.73 means that, adjusted for clinic, a patient in the given arm attends 73% of visits scheduled between their index visit and the study end date.
|
From index visit to end of study data collection, an average of 512 days
|
|
Prescription Refill Rate (Probability That Proportion Days Covered >= 80%)
Time Frame: 6 months
|
This outcome tests the hypothesis that prescription adherence improves in patients when they have access to an audio recording of their discussion with their provider compared to when they do not.
Adherence is defined as having at least 80% proportion days covered (PDF).
PDC is the total number of days covered by refills in a measurement period divided by the number of days between the first fill and the end of the measurement period.
Non-adherence is defined as a PDC<80% during the 6 months prior to the audio recorded visit.
The outcome is the probability that a patient's PDC is at least 80% following their participation, adjusted for clinic.
|
6 months
|
|
SEGUE Framework for Evaluating and Scoring Communication Behavior.
Time Frame: Recorded visit
|
This outcome tests the hypothesis that physicians communicate more effectively when they are aware the visit is being recorded for the patient to when they are not.
Communication behavior will be rated off the audio recording by a research assistant utilizing the SEGUE checklist.
Outcome measure is total proportion achieved score on 32 item SEGUE instrument, ranging from 0 to 1 with a higher score indicating more effective communication.
|
Recorded visit
|
|
Contextualization of Care
Time Frame: Recorded visit
|
This outcome tests the hypothesis that physicians are more likely to contextualize the care plan when they are aware the visit is being recorded for the patient to when they are not.
Contextualization of care will be rated off of the audio recording by a research assistant trained in Content Coding for Contextualization of Care (4C Coding), which determines each contextual red flag audible during the visit, whether the physician probed each red flag, each contextual factor identified by physician probe, and whether the physician addressed the contextual factor in the care plan.
Outcome measure is the predicted probability of an encounter in which the care plan was contextualized (either the physician found no contextual factors present after investigating red flags, or physician found a contextual factor(s) and incorporated them into the plan), adjusted for clinic.
|
Recorded visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emergency Department Utilization
Time Frame: 6 months
|
This outcome tests the hypothesis that emergency department visit rates are lower following encounters in which patients have access to an audio recording of their visit with their provider compared to when they do not.
Outcome measure is the average number of ED visits made by the patient in the 6 months following the audio recorded visit, adjusted for clinic.
|
6 months
|
|
Hospital Admission Rate
Time Frame: 6 months
|
This outcome tests the hypothesis that inpatient admission rates are lower following encounters in which patients have access to an audio recording of their visit with their provider compared to when they do not.
Outcome measure is the average number of inpatient hospital admissions of the patient (of any duration) during the 6 month period following the audio recorded visit.
|
6 months
|
|
Glycated Hemoglobin (Access vs. Non-access)
Time Frame: Six month
|
Comparison of HgA1c among Arm 1 patients who did and did not access their visit recording
|
Six month
|
|
ED Visit Rate (Access vs. Non-access)
Time Frame: Six month
|
Comparison of ED visit rate among Arm 1 patients who did and did not access their visit recording.
The ED visit rate is the number of emergency department visits in the 6 months following the patient's recorded visit, adjusted for clinic.
|
Six month
|
|
Return Visit Attendance (Access vs. Non-access)
Time Frame: From recorded visit to study end date, an average of 512 days
|
Comparison of RVA among Arm 1 patients who did and did not access their visit recording.
The outcome is the predicted proportion of visits scheduled between the time of the index visit and the end of the study that the patient attends (adjusted for clinic).
For example, a value of 0.73 means that, adjusted for clinic, a patient in the given arm attends 73% of visits scheduled between their index visit and the study end date.
|
From recorded visit to study end date, an average of 512 days
|
|
Probability That Proportion of Days Covered by Prescription >= 80% (Access vs. Non-access)
Time Frame: 6 months
|
Comparison of probability of prescription refill adherence (PDC>=80%) among Arm 1 patients who did and did not access their visit recording.
Adherence is defined as having at least 80% proportion days covered (PDF).
PDC is the total number of days covered by refills in a measurement period divided by the number of days between the first fill and the end of the measurement period.
Non-adherence is defined as a PDC<80% during the 6 months prior to the audio recorded visit.
The outcome is the probability that a patient's PDC is at least 80% following their participation, adjusted for clinic.
|
6 months
|
|
Blood Pressure (Access vs. Non-access)
Time Frame: Six month
|
Comparison of blood pressure among Arm 1 patients who did and did not access their visit recording
|
Six month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Saul J. Weiner, MD, Jesse Brown VA Medical Center, Chicago, IL
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2021
Primary Completion (Actual)
July 31, 2024
Study Completion (Actual)
July 31, 2024
Study Registration Dates
First Submitted
June 25, 2020
First Submitted That Met QC Criteria
June 25, 2020
First Posted (Actual)
June 30, 2020
Study Record Updates
Last Update Posted (Actual)
April 3, 2025
Last Update Submitted That Met QC Criteria
March 13, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIR 19-068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on Open Access Audio
-
Zhejiang UniversityWestlake University; University of Chinese Academy of SciencesRecruitingActive Control | Focused-attention Meditatioin | Open-monitoring MeditationChina
-
Wilhelminenspital ViennaCompletedAortic AneurysmAustria
-
University of AarhusCentral Denmark Region; TrygFonden, DenmarkCompleted
-
Rigshospitalet, DenmarkCompletedSpinal MetastasesDenmark
-
Norwegian Department of Health and Social AffairsCompletedStomach Diseases | Esophageal Diseases | Peptic UlcerNorway
-
Siriraj HospitalNot yet recruitingHypnosis, Mindfulness Meditation
-
Dartmouth-Hitchcock Medical CenterNational Library of Medicine (NLM)CompletedMultimorbidityUnited States
-
Massachusetts General HospitalCompleted
-
Duke UniversityNational Institutes of Health (NIH); Durham VA Medical CenterCompletedStress Disorder, Post Traumatic | Military Sexual TraumaUnited States
-
Stanford UniversityWithdrawn